Sotio AS logo

Sotio AS

SOTIO is a clinical stage biotechnology company developing a new Active Cellular Immunotherapy (_ACIÓ) based on activated dendritic cells for the treatment of cancer and autoimmune diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.sotio.com/
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Jankovcova 1518/2, 170 00
Prague 7
Czech Republic
Email
Contact Number
+420 224 175 111

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/sotio-a.s.” connections=”true” suffix=””]

SOTIOs proprietary ACI-MAP (Active Cellular Immunotherapy Multiple Antigen Presentation) technology, the patients own dendritic cells, are activated by a broad range of tumor antigens, to induce a complex immune response.

In Aug 2018, SOTIO, acquired Cytune Pharma developing IL-15 based therapies for the treatment of cancer. Cytunes lead molecule, SO-C101 (RLI-15), is a human fusion protein of IL-15 and the high-affinity binding domain of IL-15R? and acts as a specific IL-2/IL-15R?? agonist. The financial terms of the transaction are not disclosed.